Dyax shares score on HAE drug 'breakthrough' status
This article was originally published in Scrip
Executive Summary
Shares of Dyax jumped about 5% in morning trading on 7 July on word the FDA had granted breakthrough therapy designation (BTD) – a mechanism intended to help expedite the regulatory process for medicines aimed at treating serious conditions – for the company's investigational hereditary angioedema (HAE) drug of DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein (pKal).